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Abstract: Ingestion of pure fructose stimulates de novo lipogenesis and gluconeogenesis. 
This may however not be relevant to typical nutritional situations, where fructose is 
invariably ingested with glucose. We therefore assessed the metabolic fate of fructose 
incorporated in a mixed meal without or with glucose in eight healthy volunteers. Each 
participant was studied over six hours after the ingestion of liquid meals containing either  
13C-labelled fructose, unlabeled glucose, lipids and protein (Fr + G) or 13C-labelled 
fructose, lipids and protein, but without glucose (Fr), or protein and lipids alone (ProLip). 
After Fr + G, plasma 13C-glucose production accounted for 19.0% ± 1.5% and 13CO2 
production for 32.2% ± 1.3% of 13C-fructose carbons. After Fr, 13C-glucose production  
(26.5% ± 1.4%) and 13CO2 production (36.6% ± 1.9%) were higher (p < 0.05) than with  
Fr + G. 13C-lactate concentration and very low density lipoprotein VLDL 13C-palmitate 
concentrations increased to the same extent with Fr + G and Fr, while chylomicron  
13C-palmitate tended to increase more with Fr + G. These data indicate that 
gluconeogenesis, lactic acid production and both intestinal and hepatic de novo lipogenesis 
contributed to the disposal of fructose carbons ingested together with a mixed meal.  
Co-ingestion of glucose decreased fructose oxidation and gluconeogenesis and tended to 
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increase 13C-pamitate concentration in gut-derived chylomicrons, but not in hepatic-borne 
VLDL-triacylglycerol (TG). This trial was approved by clinicaltrial. gov. Identifier  
is NCT01792089. 
Keywords: fructose oxidation; gluconeogenesis; glucose production; de novo lipogenesis; 
hepatic; intestinal; sugar 
 
1. Introduction 
Fructose intake has increased progressively over the past 30 years and currently averages about  
50–60 g/day in the U.S. and in several European countries [1,2]. There is much concern that this may 
contribute to the rise in prevalence of obesity and metabolic disorders observed over the same period [3]. 
This is mainly based on the observation that a high-fructose-containing diet causes obesity, diabetes 
mellitus, dyslipidemia and hepatic steatosis in rodents [4,5] and that short-term fructose overfeeding 
increases fasting and postprandial triacylglycerol (TG), decreases hepatic insulin sensitivity and 
increases intrahepatic fat in humans. 
Several short-term studies, using 13C-fructose as a metabolic tracer, have documented that fructose 
exerts specific metabolic effects, which may indeed contribute to the pathogenesis of insulin resistance 
and dyslipidemia. Fructose is largely extracted by splanchnic organs (gut and liver), where it is 
essentially converted into glucose, lactate and fatty acid, which can subsequently be used as an energy 
substrate by extrahepatic cells. After the administration of a large 13C-labelled fructose load, within  
4–6 h, approximately 50% of the labelled carbons are recovered as breath 13CO2, indicating that  
50% are temporarily retained in the body’s energy stores [6–8]; over the same period, about 30%–50% 
is released in the blood as 13C-labelled glucose [6–8] and an unspecified amount is released as  
13C-labelled lactate. The oxidation of these newly synthesized substrates obviously contributes to total 
breath 13CO2 production, but the relative amounts of 13C glucose being immediately oxidized in  
extra-hepatic tissues and stored as extra-hepatic (mainly muscle) glycogen is not known. After 
intravenous administration, hepatic and muscle glycogen synthesis account each for about 25% of total 
fructose infused [9], but similar data are not available for oral fructose administration. Labelled carbon 
atoms are also recovered as very low density lipoprotein VLDL-fatty acids, indicating that hepatic  
de novo lipogenesis is active after fructose ingestion [10]. Tracer studies using 13C-acetate as a 
lipogenic precursor further indicate that fructose is substantially more lipogenic than glucose [11].  
De novo lipogenesis is generally assumed to occur in the liver, but may also take place in the  
gut [12,13]. It is enhanced by the consumption of a high fructose diet [14], and contributes, together 
with a decrease of TG-rich lipoprotein clearance [15,16], to fructose-induced hypertriglyceridemia. 
The relevance of studies assessing the effects of pure fructose on the pathogenesis of metabolic 
diseases is often questioned, as dietary fructose is mainly present in fructose-containing caloric 
sweeteners (sucrose, high fructose corn syrup), fruits and honey, which all contain roughly equimolar 
amounts of fructose and glucose. Co-ingestion of glucose or other nutrients may indeed significantly 
alter the metabolic fate of fructose due to changes in glucoregulatory hormone concentrations.  
In addition, glucose and fructose are expected to mutually enhance their splanchnic metabolism, since 
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the presence of glucose in the gut lumen increases intestinal fructose absorption, on the one hand [17], 
and fructose-1-P activates hepatic glucokinase, resulting in hepatic glucose metabolism and glycogen 
storage, on the other hand [18]. The aim of the present study was to assess the metabolic fate of 
fructose and its interaction with other nutrients present in a mixed meal. For this purpose, we 
monitored, in healthy human volunteers, the metabolic response to a liquid meal containing protein, 
fat, glucose and 13C-labelled fructose and to the same liquid meal in which glucose only or both 
glucose and fructose were omitted. These measurements were performed after subjects had consumed 
a weight-maintenance diet containing 20% sucrose for three days. 
2. Experimental Section  
2.1. Subjects Inclusion 
Eight healthy non obese volunteers (4 males, 4 females) with a mean (±SEM) age and BMI of  
26.4 ± 1.0 year and 21.9 ± 0.7 kg/m2, respectively, were included in a randomized, crossover study. 
Participant characteristics are shown in Table 1. All subjects were non-smokers, had low habitual 
physical activity, were not currently taking any medication and had no family history of diabetes. 
Before inclusion, they underwent a physical examination to ensure good physical health. The 
experimental protocol was approved by the Ethical Committee of Lausanne University School of 
Medicine. All participants provided written informed consent. 
Table 1. Baseline characteristics of the studied participants (mean ± SD). 
 Mean ± SD 
Age (year) 26.4 ± 1.0 
Body weight (kg) 63.7 ± 2.4 
Body mass index (kg/m2) 21.9 ± 0.7 
Body fat (%) 20.6 ± 1.9 
Systolic blood pressure (mmHg) 118 ± 3 
Diastolic blood pressure (mmHg) 70 ± 3 
Heart rate (beats/min) 74 ± 3 
2.2. Study Design  
Each volunteer was studied on three different occasions according to a randomized cross-over 
design. On each occasion, participants first consumed a controlled weight-maintenance diet (basal 
energy requirements calculated with the Harris-Benedict equation times a physical activity factor  
of 1.5) containing 55% carbohydrate (35% complex carbohydrate and 20% sugar), 15% protein and  
30% fat during 3 days. During this period, they were asked to have minimal physical activity and to 
abstain from alcohol or caffeine-containing beverages. On the fourth day, subjects came to the Clinical 
Research Center of Lausanne University Hospital at 7:00 am in the fasting state and underwent a 
metabolic test with the ingestion of 1 of the 3 following test meals: 
Fr + G (glucose) meal: a liquid meal containing 7.99 ± 0.14 kcal/kg, 0.3 g/kg lipid (from cream), 
0.3 g/kg protein (from Whey Protein 94, Sponser, Wollerau, Switzerland), 0.5 g/kg glucose (in 2 mL 
water) and 0.5 g/kg fructose (in 2 mL water). Fructose was labelled with 1% U-13C6-fructose 
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(Cambridge Isotope Laboratories, Tewksbury, MA, USA). This meal accounted for 30% of their daily 
energy needs (calculated as basal energy requirements times 1.1 to account for very low physical 
activity during the test and for an expected thermic effect of food equal to 10% of the total  
energy requirements). 
Fr (fructose) meal: a liquid meal containing 5.99 ± 0.09 kcal/kg, 0.3 g/kg lipid (from cream),  
0.3 g/kg protein (from Whey Protein 94, Sponser, Wollerau, Switzerland) and 0.5 g/kg fructose  
(in 2 mL water). Fructose was labelled with 1% U-13C6-fructose. This meal accounted for 22% of the 
daily energy needs. 
ProLip (protein and lipid) meal: a liquid meal containing 4.01 ± 0.06 kcal/kg, 0.3 g/kg lipid (from 
cream) and 0.3 g/kg protein (from Whey Protein 94, Sponser, Wollerau, Switzerland). This meal 
accounted for 15% of the daily energy needs.  
The order of administration of the three meals was randomized, and a washout period of  
3–10 weeks was allowed between metabolic tests. 
2.3. Metabolic Tests 
Each metabolic test included 2-h fasting and 6-h postprandial measurements, as depicted in Figure 1. 
Figure 1. Graphical representation of metabolic tests. ProLip, protein and lipid;  
Fr, fructose; G, glucose. 
 
On arrival, subjects were weighed and the body composition assessed by bio-electrical impedance 
(Imp Df 50; ImpediMed, Pinkenba, Australia). Subjects were asked to void their bladder, and the 
collected urine was discarded, with all urine thereafter collected until the end for the determination of 
the urinary urea nitrogen excretion rate. Subjects were then transferred to a bed, where they remained 
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quiet, but awake for the next eight hours. A venous catheter was inserted into a forearm vein and was 
used for blood sampling. A second catheter was inserted into an antecubital vein of the other arm and a  
primed-continuous infusion of tracer amounts of 6,6-2H2-glucose (Cambridge Isotope Laboratories, 
Cambridge, MA, U.S.; bolus 2.8 mg/kg, continuous infusion 40 μg/kg/min) was administered through 
this catheter throughout the metabolic test to calculate whole body glucose rates of appearance (GRa) 
and of disappearance (GRd) [7,8]. Respiratory gas exchange was monitored throughout the experiment 
by open circuit indirect calorimetry (Quark RMR, version 9.1b, Cosmed, Rome, Italy). Energy 
expenditure and net substrate oxidation were calculated using the equations of Livesey and Elia [19]. 
Due to technical problems, results could not be obtained for 2 subjects during one of the three meals. 
Data collected during the other two meals in these two subjects were not taken into consideration to 
avoid introducing bias in paired statistical analyses. Blood samples were collected at Time 0 
immediately before starting the 6,6-2H2-glucose administration (T = 0 min) and after two hours spent 
in fasting conditions (T = 120 min); thereafter, subjects consumed their test meal over a 15-min period 
(T = 120 min), during which indirect calorimetry was interrupted and blood samples were collected at 
T = 150, 180, 210, 240, 270, 300, 360, 420, 480 min. Hormones and metabolites, plasma  
6,6-2H2-glucose, 13C-lactate and 13C-glucose enrichments and VLDL- and chylomicron-TG 
concentration and 13C-palmitate enrichment in chylomicron and VLDL subfractions on each blood 
sample were measured. Breath samples were collected for the measurement of 13CO2 isotopic 
enrichment at T = 0, 60, 120, 180, 240, 300, 360, 420 and 480 min when subjects had the Fr and  
Fr + G meals, and at T = 0, 120, 240, 360 and 380 min when they had the ProLip meal.  
2.4. Analytical Procedures 
Plasma was immediately separated from blood cells by centrifugation at 1230× g for 10 min at  
4 °C, and plasma aliquots were stored at −20 °C. Plasma metabolites (glucose, TG, non-esterified fatty 
acids (NEFAs), cholesterol, HDL-cholesterol, uric acid and lactate) and urinary urea were measured by 
enzymatic methods (Randox Laboratories, Crumlin, UK). Insulin and glucagon were assessed by 
radioimmunoassay (Millipore, Billerica, MA, USA). Plasma apolipoprotein B (apoBtot) and 
apolipoprotein B48 (apoB48) were measured by ELISA using kits from Shibayagi, Shibukawa, Japan 
and R & D Systems LTD, Abingdon, UK Plasma and urinary fructose concentrations and  
plasma 6,6-2H2-glucose isotopic enrichment were measured by gas chromatography-mass spectrometry 
(GC-MS). Two-point-three micromolar 1,2,3 13C3 D-fructose was added to 250 mL plasma or urine as 
an internal standard. Plasma or urine samples were thereafter deproteinized using the ZnSO4-Ba(OH)2 
method [20], partially purified over anion- and cation-exchange resins and derivatized with acetic 
anhydride and pyridine. Samples were then dried under a stream of nitrogen and resuspended in 60 μL 
ethyl acetate, and 1 μL was analyzed by GC-MS (Agilent Technologies, Santa Clara, CA, USA) in 
electron impact mode, with selected monitoring of m/z 275 and 277. The fructose concentration in 
samples was determined from the ratio of m/z 277 to m/z 275 by means of an unlabeled pure fructose 
standard curve. Plasma 6,6-2H2 glucose enrichment was measured on pentaacetyl-derivates, suing  
GC-MS in chemical ionization mode with selective monitoring of m/z 333 and m/z 331. Plasma  
13C-lactate enrichments were measured on lactic n-propylamide heptafluorobutyrates, with selective 
monitoring of m/z 331 and m/z 328. Plasma 13C-glucose isotopic enrichment was measured by  
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gas-chromatography-isotope ratio mass spectrometry (GC-C-IRMS), as described [8]. Plasma 
lipoprotein subfractions were separated by ultracentrifugation, and fractions Sf > 400 (chylomicrons) 
and Sf 20–400 (VLDL and chylomicron remnants) were isolated. Fatty acid methyl esters (FAMEs) 
from chylomicron- and VLDL-TG were isolated, and their 13C enrichment was measured by gas 
chromatography-isotope ratio mass spectrometry (Thermo Electron, Bremen, Germany), as  
described [21]. Tricosanoic acid methyl ester was used as an isotopic enrichment standard, and a 
quality-control sample (certified standard of eicosanoic acid FAME; Department of Geological 
Sciences, Indiana University, Bloomington, IN, USA) was run with each set of samples.  
2.5. Calculations 
Glucose rate of appearance (GRa) was calculated with 6,6-2H2-glucose as:  
GRa (mg/min) = F + {[p × V × BW × (G(t1)/2) + (G(t2)/2)] × [(E(t1)/2 − 
E(t2)/2)]}/[(E(t1)/2 + E(t2)/2) × (t2 − t1)] (1) 
where F = 6,6-2H2-glucose infusion rate (mg/min), p = pool fraction, set at 0.65, BW = body weight 
(kg), V = glucose distribution volume, set at 0.2, G = glucose concentration (mg/L), E = 6,6-2H2-
glucose isotopic enrichment (mol% excess) and t = time of collection (min) [22]. Parameters were set 
assuming that kinetics for 13C-glucose appearance in blood after ingestion of a 13C-labelled glucose 
load apply to the ingestion of a 13C-labelled fructose load, as well [23]. 
Gluconeogenesis from fructose (GNGf) was calculated as:  
GNGf (mg/min) = {GRa × [(13CG(t1) + 13CG(t2))/2] + p × V × [(G(t1)+G(t2))/2] × 
[(13CG(t2) − 13CG(t1)1)/(t2 − t1)]}/13C-fructose (2)
where 13CG = plasma 13C-glucose isotopic enrichment and 13C-fructose = meal 13C-fructose isotopic 
enrichment (at% excess). 
Fructose oxidation (Fox) was calculated as:  
Fox (mg/min) = 180 × (13CO2(tx)/13C-fructose(tx)) × (VCO2(tx))/(22.29 × 6 × 0.8) (3)
where 13CO2 = breath CO2 isotopic enrichment (atom% excess), VCO2 = total CO2 production (L/min) 
and tx = time of collection; 22.29 mL CO2 was assumed to correspond to 1 mmol CO2; six mmol CO2 
correspond to 1 mmol = 180 mg fructose; 0.8 is the recovery factor of 13CO2 in breath. 
Non-oxidative fructose disposal (NOFD) was calculated as:  
NOFD (mg/360 min) = (ingested fructose (g)) − (fructose oxidation, cumulated 
between 120 and 480 min (g)) 
(3)
The amount of 13C-glucose and 13C-lactate remaining in blood 6 hours after meal ingestion was low 
(<2 g) and was neglected in this calculation. 
Net substrate oxidations and energy expenditure (EE) were calculated from standard indirect 
calorimetry equations [19], assuming that total nitrogen excretion was equal to (urinary urea nitrogen 
excretion)/0.85 [24].  
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For each meal, diet-induced thermogenesis was calculated as:  
diet-induced thermogenesis (%) = 100 × (postprandial EE (kcal/360 min)) −  
(pre-prandial EE (kcal/min × 360 min))/(energy content of the meal kcal) 
(4)
2.6. Statistical Analysis 
Results are expressed as mean ± SEM. The normality of data and differences was checked with 
Shapiro-Wilk tests for all parameters analyzed. Non-normally distributed data (glucagon, TG,  
VLDL-TG) were log-transformed before statistical analysis. All variables measured at different time 
points after ingestion of test-meals were reduced to a single value by calculating their average or 
cumulated postprandial values (gluconeogenesis from fructose, fructose oxidation, glycogen synthesis, 
net substrate oxidation, energy expenditure) or their cumulated incremental area under the curve values 
(iAUC: plasma concentrations of metabolites or hormones) over the 360-min postprandial period. 
Between test-meals, comparisons were performed on these single postprandial values by ANOVA 
followed by pots hoc paired t-tests with Bonferroni’s correction. A difference was considered 
significant when the Bonferroni-corrected p-value was <0.05. All statistical analyses were performed 
using STATA version 10 (Stata Corp, College Station, USA). 
3. Results  
3.1. Anthropometric Variables and Fasting Parameters 
Fasting plasma glucose and insulin concentrations, body weight and body composition after three 
days on a controlled, weight maintenance diet were similar before each test meal (Table 2). 
Table 2. Fasting parameters. 
 ProLip Fr Fr + G 
Plasma glucose (mmol/L) 4.74 ± 0.15 4.79 ± 0.08 4.67 ± 0.10 
Plasma insulin (pmol/L) 54.2 ± 5.6 57.4 ± 4.7 54.3 ± 3.6 
Body weight (kg) 63.4 ± 2.4 63.7 ± 2.4 63.6 ± 2.4 
Lean body mass (kg) 51.1 ± 2.4 50.0 ± 2.5 50.4 ± 2.5 
Fat mass (kg) 12.3 ± 1.1 13.7 ± 0.8 13.0 ± 1.0 
All values are mean ± SEM; n = 8 subjects. 
3.2. Effects on Carbohydrate Metabolism 
After ingestion of Fr + G, plasma glucose and insulin increased rapidly, peaking after 150 min, and, 
thereafter, declined progressively. Plasma glucagon concentrations were significantly decreased  
(p = 0.033) compared to ProLip (Figure 2).  
Plasma fructose concentrations increased to an average peak value of 231 ± 37 μmol/L at 180 min 
and decreased rapidly thereafter (Figure 3). Plasma lactate and 13C-lactate concentrations also 
increased significantly and showed the same time-course as glucose (Figure 3). Plasma 13C-lactate 
enrichment averaged 0.15% mol% excess. Over the six hours after meal ingestion, since the 
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enrichment of fructose in the meal was set at 1 mol% excess, this indicates that fructose contributed to 
approximately 15% of the total lactate production.  
After Fr, the increase in plasma glucose and insulin concentrations was markedly blunted compared 
to Fr + G (Figure 2). In contrast, the increase in plasma fructose was of a similar magnitude as  
Fr + G. Plasma lactate and glucagon concentrations and plasma 13C-lactate isotopic enrichment were 
also not significantly different than after Fr + G (Figure 3). After ProLip, plasma glucose, fructose, 
insulin and lactate concentrations were minimally altered, but the rise in the plasma glucagon 
concentration was significantly higher than after Fr + G (Figures 2 and 3). 
The release of fructose carbons as glucose in the systemic circulation were calculated from plasma 
6,6-2H2- and 13C-glucose isotopic enrichments (shown in Figure 4), which allowed calculating GRa 
and GNGf, respectively, while the total oxidation of fructose was calculated from breath 13CO2 
isotopic enrichment (Figure 4) and total CO2 production.  
Figure 2. Plasma glucose, insulin and glucagon responses to meal ingestion. The time 
course for plasma glucose (A), plasma insulin (C), plasma glucagon concentrations and 
their corresponding incremental area under the curve (iAUC) values (B, D and F)  
(mean ± SEM, n = 8). Test meals were given at t = 120 min. iAUC were compared by  
t-tests with Bonferroni’s correction. Glucagon was log-transformed before statistical 
analysis. ProLip, lipid and protein; Fr, lipid, protein and fructose; Fr + G, lipid, protein, 
fructose and glucose. * p < 0.05 vs. ProLip; $ p < 0.05 vs. Fr. 
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Figure 3. Plasma fructose, lactate and 13C-lactate responses to test meal ingestion. Time 
course for plasma fructose (A), lactate (C) and 13C-lactate concentrations (E) and their 
corresponding iAUC (B, D and F) (n = 8). * p < 0.05 vs. ProLip; $ p < 0.05 vs. Fr. 
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Figure 4. Plasma 6,6-2H2-glucose (A), plasma 13C-glucose (B) and breath 13CO2 (C) 
isotopic enrichments. (Mean ± SEM, n = 8). Test meals were given at t = 120 min.  
MPE: molar percent excess; APE: atom percent excess. 
Over the 6 h following Fr + G ingestion, 33% of the ingested fructose was oxidized to CO2, and the 
remaining 67% was disposed of non-oxidatively (Table 3). Ingestion of Fr + G increased GRa from 
2.09 ± 0.12 mg/kg/min in the basal condition to a mean postprandial value of  
3.07 ± 0.12 mg/kg/min. With Fr, total GRa, cumulated over six hours postprandial, was lower, but 
GNGf, cumulated over the same period, was higher than with Fr + G. Cumulated fructose oxidation 
was also significantly higher and corresponded to 37% of ingested fructose, while non-oxidative 
fructose disposal was lower (Table 3). With ProLip, GRa was only marginally increased (basal:  
2.09 mg/kg/min vs. average postprandial 2.22 mg/kg/min, NS) and, when cumulated over six hours 
postprandial, was comparable with that observed with Fr (Table 3). 
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Table 3. Total glucose rate of appearance (GRa, n = 8), fructose oxidation, total net 
carbohydrate oxidation (total carbo. ox., n = 6), gluconeogenesis from fructose (GNGf,  
n = 8) and non-oxidative fructose disposal (NOFD, n = 6) cumulated over six hours after 
the ingestion of test meals. * p < 0.05 vs. ProLip, $ p < 0.05 vs. Fr. 
 ProLip  Fr Fr + G 
GRa (g/360 min) 50.98 ± 2.47 53.78 ± 2.20 69.86 ± 2.51 *,$ 
Fructose oxidation (g/360 min)  12.64 ± 0.67 11.30 ± 0.74 $ 
Total carbo. ox. (g/360 min) 25.92 ± 1.93 22.16 ± 1.91 25.87 ± 4.73 
GNGf (g/360 min)  9.03 ± 0.15 6.54 ± 0.17 $ 
NOFD (g/6 h)  21.78 ± 0.96 22.90 ± 0.97 $ 
3.3. Effects on Lipid Metabolism 
With Fr + G, TG, VLDL-TG, chylomicron-TG and apoB48 concentrations and 13C-palmitate 
isotopic enrichment in chylomicrons and in VLDL-TG, all increased progressively to peak at around 
four hours after meal ingestion (Figures 5 and 6). Plasma apoBtot concentrations did not change after 
meal ingestion, however. Plasma NEFA decreased transiently after ingestion of the meal and, 
thereafter, progressively increased. Postprandial net lipid oxidation amounted to 15.0 ± 4.1 g/360 min. 
With Fr, plasma TG, VLDL-TG and chylomicron-TG plasma apoB48 and plasma apoBtot responses 
were not significantly different from Fr + G. 13C-palmitate isotopic enrichment in VLDL-TG was also 
not different, but 13C-palmitate enrichment in chylomicron-TG tended to be lower with Fr than with  
Fr + G (p = 0.08; Figure 6). Total net lipid oxidation accounted for 16.5 ± 5.3 g/360 min. 
With ProLip, postprandial plasma total TG concentrations were lower than with Fr (p < 0.05), but 
were not significantly different from Fr + G. VLDL-TG, chylomicron-TG and plasma ApoB48 
concentrations did not show any significant differences with Fr + G or Fr (Figures 5 and 6). Net lipid 
oxidation amounted to 18.0 ± 5.6 g/360 min and was not significantly different from Fr or Fr + G. 
Figure 5. Plasma NEFA (A), total TG (C), VLDL-TG (E) and chylomicron-TG (G) 
responses to test meal ingestion and their corresponding iAUC (B, D, F and H) (n = 8).  
* p < 0.05 vs. ProLip, $ p < 0.05 vs. Fr. 
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Figure 5. Cont. 
 
Figure 6. Plasma ApoB48 (A), ApoBtot (B), 13C-palmitate-VLDL (E), 13C-palmitate-
chylomicrons (G) (n = 8). Additionally, their corresponding iAUC (B, D, F and H) (n = 8). 
* p < 0.05 vs. ProLip, $ p < 0.05 vs. Fr. 
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Figure 6. Cont. 
 
3.4. Effects on Energy Expenditure and Diet-Induced Thermogenesis 
Basal energy expenditure was similar for all three test meals: ProLip: 1.05 ± 0.08 kcal/min;  
Fr: 1.07 ± 0.08 kcal/min; Fr + G: 1.00 ± 0.06 kcal/min. Postprandial energy expenditure, averaged over 
a 360-min postprandial period, tended to be higher with Fr (1.15 ± 0.08 kcal/min, p = 0.06), but not 
with Fr + G (1.13 ± 0.07 kcal/min, p = 0.31, NS) compared to ProLip (1.09 ± 0.08 kcal/min,).  
Diet-induced thermogenesis did not significantly differ between the three meals (Fr + G: 9% ± 1%;  
Fr: 7% ± 2%; ProLip: 7% ± 1%, NS). 
4. Discussion  
The measurements obtained in this study provide novel insights into the metabolic fate of fructose 
when ingested as part of a mixed meal. The experimental design involved the ingestion of three 
different protein- and fat-based drinks, one containing 13C- labelled fructose and unlabeled glucose in 
equimolar amounts (Fr + G), one containing the same amount of 13C fructose, but without glucose (Fr), 
and one containing neither fructose nor glucose (ProLip). Since the amount of 13C fructose ingested 
was the same in Fr + G and Fr, comparing the appearance of 13C in breath CO2 and in plasma 
metabolites provided information on how the co-ingestion of glucose impacted the metabolic fate of 
fructose; in addition, since the amount of lipid was the same in all three meals, comparing the 
postprandial plasma TG responses provided information on how glucose and fructose impacted on 
postprandial lipemia. 
4.1. Metabolic Fate of Fructose Ingested together with Equimolar Amounts of Glucose 
When both 13C-fructose and glucose were present in the drink, about one third of the ingested 13C 
fructose carbons were recovered as breath 13CO2 over 360 min after ingestion of Fr + G. This 
represents both the oxidation of fructose in splanchnic organs and extrahepatic oxidation of some 
newly synthesized glucose and lactate released into the systemic circulation. The methods used in this 
study do not allow us to evaluate the relative importance of each pathway to total fructose oxidation. 
Assuming that exogenous fructose was completely absorbed from the gut after 360 min, one can 
nonetheless conclude that about 70% of the ingested fructose load was deposited into the body energy 
stores, either as glycogen or as TG in the liver or in extrahepatic tissues.  
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Ingestion of the mixed meal containing both labelled fructose and unlabeled glucose caused a small 
transient increase in plasma fructose concentration, but a significant incorporation of 13C in plasma 
glucose, lactate, VLDL-TG and chylomicron-TG. This is consistent with an extensive fructose uptake 
in splanchnic organs and its conversion into glucose, lactic acid and lipids [24]. The contribution of 
13C-glucose synthetized from 13C-fructose to whole body glucose fluxes could be quantified with the 
simultaneous use of 6,6-2H2 glucose and accounted for 19.0% ± 1.5% of ingested fructose over the  
360 min postprandial period. This is an underestimate of total hepatic gluconeogenesis from fructose, 
however, since part of the newly formed glucose was likely to be retained within intrahepatic 
glycogen. Plasma 13C-lactate isotopic enrichments indicate that about 15% of circulating lactate was 
produced from fructose, presumably in the gut and liver. However, the amount of lactate actually 
produced from fructose could not be quantified, since lactate turnover was not measured. 
There was also a significant incorporation of labelled carbons into both VLDL- and  
chylomicron-palmitate. The bulk of 13C-palmitate was detected in the VLDL-TG fraction, corroborating 
earlier reports that fructose ingestion stimulates de novo lipogenesis in liver cells [1,15,25]. In 
addition, we observed an incorporation of 13C in chylomicron-palmitate, indicating that some fructose 
was converted into TG within enterocytes, as reported in high fructose-fed rodents [12], and more 
recently in humans [14,26]. The concentration of 13C-palmitate in chylomicron-TG was about one third 
of that observed in VLDL-TG, but this may underestimate the relative contribution of the gut to total 
de novo lipogenesis, since chylomicrons have a shorter half-life and, hence, a higher turnover rate than  
VLDL [27]. The total amount of fructose converted into fat during these experiments could not be 
quantified, because we used a semi-quantitative isotopic approach, thus we could not actually measure 
the isotopic enrichment of intrahepatic acetyl-coA from which fatty acids are synthesized; we did not 
quantitatively assess the VLDL- and chylomicron-TG secretion rate, nor whether newly-synthesized 
fatty acids were being stored as intrahepatic fat [28]. Furthermore, 13C-palmitate concentrations 
measured in plasma lipoproteins reflected only the conversion of 13C-fructose into lipids, but not the 
contribution of unlabeled glucose carbons. 
4.2. Modulation of Fructose Metabolism by Glucose 
Postprandial plasma fructose concentrations were identical when the test meal included fructose 
alone and both fructose and glucose. This suggests that glucose in the gut lumen did not significantly 
alter splanchnic fructose extraction. This may appear surprising, since fructose absorption is known to 
be quantitatively limited when pure fructose is ingested alone [29], but to be facilitated by  
glucose [28]. The fructose load ingested with the test-meals was relatively small and, hence, may not 
have exceeded gut fructose absorptive capacity; furthermore, it is possible that fructose transport had 
been upregulated as a consequence of having consumed a 20% sucrose diet during the several days prior 
to the experiments [30]. 
More labelled fructose carbons were recovered as breath 13CO2 when fructose was added alone to 
the protein and fat meal than with glucose. In addition, a larger portion of labelled fructose carbons 
was released as plasma glucose, while plasma lactate and 13C-lactate concentrations were not altered 
significantly. We can therefore conclude that glucose inhibited gluconeogenesis from fructose, while, 
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at the same time, enhancing the storage of fructose carbons, presumably as hepatic glycogen. 
However, this difference represented only 1.5 g or about 5% of ingested fructose.  
Postprandial VLDL-13C-palmitate, plasma apoBtot and apoB48 concentrations were not 
significantly different when fructose was ingested alone or together with glucose. This suggests that 
co-ingestion of glucose had not grossly altered the proportion of ingested fructose, which was 
converted into fat in the liver. In contrast, postprandial the chylomicron-13C-palmitate response tended 
to be higher when glucose was co-ingested with fructose, suggesting that intestinal de novo lipogenesis 
may have been enhanced by glucose [31]. 
4.3. Effects of Fructose and Glucose on Dietary Lipid Handling 
After the ingestion of a protein and lipid meal devoid of carbohydrate, total-, chylomicron- and  
VLDL-TG and plasma apoB48 concentrations all increased progressively to reach a maximum after 
about three hours and progressively decreased thereafter. When fructose alone or both fructose and 
glucose were added to the meal, the initial TG response was not altered, but the rises in total, 
chylomicrons and VLDL-TG were extended for an additional hour; and the integrated TG response 
tended to be larger. The difference only attained statistical significance when comparing the effects of 
the protein and lipid meal with and without fructose alone. Plasma apoBtot and apoB48 responses 
were not altered, suggesting that the effect of fructose may be due to an increased de novo lipogenesis 
rather than to an impaired extra-hepatic clearance of TG-rich lipoproteins. Taken together, our results 
corroborate the finding that fructose added to a meal enhances postprandial blood lipids [32] and 
further indicate that co-ingestion of glucose does not further enhance this effect. 
4.4. Limitations 
Our study has some limitations that need to be outlined. First, our experimental design involved the 
administration of three test meals with the same protein and lipid content, but differing in their fructose 
and glucose content. This was done as an attempt to assess the specific effects of fructose and its 
interaction with glucose. Thus, it resulted in comparing three energy-unbalanced test meals, and it 
remains possible that the effects on fructose metabolism that we attributed to glucose co-ingestion 
were in part due to the higher energy content of the Fr + G meal. We also considered the possibility 
that the different macronutrient composition of test meals may have altered the gastric emptying rate, 
which may have altered the rate of fructose carbon metabolism. The postprandial time course and peak 
values for plasma fructose concentration were not significantly different after the Fr and the Fr + G 
meal, which suggests that the rate of gut fructose absorption and the rate of gastric emptying were not 
altered by the addition of glucose to the Fr meal. However, it remains possible that sugars may have 
altered gastric emptying after the Fr and Fr + G meals compared to Pro-Lip and that this may have 
affected postprandial plasma TG to some extent. Second, we documented how glucose co-ingestion 
modulated the disposal of ingested fructose, but did not attempt to evaluate whether the reverse is also 
true, i.e., whether the presence of fructose in a meal alters glucose metabolism, as well. Third, we 
selected liquid test meals made of cream and purified whey protein, but devoid of starch and fiber for 
practical purposes, and cannot exclude that the metabolism of fructose ingested with a solid mixed 
meal may differ from that observed with a liquid, starch- and fiber-free meal. Finally, this study 
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included a small number of participants and may have failed to detect differences in TG-rich 
lipoprotein 13C-palmitate concentrations between Fr and Fr + G due to low statistical power. 
5. Conclusions 
Fructose included in a liquid meal containing lipid, protein and glucose is essentially extracted and 
metabolized in splanchnic organs, where it is quickly converted into glucose, lactate and fatty acids, 
thus corroborating rodent studies [12,13] and some recent human reports [14,26]. These findings are 
consistent with previous isotope studies in humans [21]. Our data further indicate that both the liver 
and the gut synthesize fat [14,24]. About two-thirds of ingested fructose remained temporarily stored 
in the body after 360 min, presumably as glycogen and lipids; present methods do not allow for the 
assessment of the relative contribution of these two processes. Co-ingestion of glucose and fructose, 
compared to fructose alone, significantly decreased fructose oxidation and gluconeogenesis and 
increased fructose carbon storage. In contrast, it did not enhance postprandial plasma lipid 
concentrations and did not alter the recovery of 13C carbons into plasma chylomicron- and VLDL-TG. 
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